NCT03265717View on ClinicalTrials.gov

DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 25, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
BIOLOGICAL

INVAC-1

Patients are treated by INVAC-1 for 6 cycles at 4-week intervals

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Invectys
All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

lead

Invectys

INDUSTRY

NCT03265717 - DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter